Assessment of Comirnaty Injections of Pregnant Women in the Manufacturer’s Risk Management Plan and by the European Medicines Agency: Mandatory Injections for Caregivers in France

Authors

  • Jérôme Sainton Independent Medical Doctor and bioethicist

DOI:

https://doi.org/10.56098/ijvtpr.v3i1.72

Keywords:

mandatory vaccination, risk-benefit analysis, Comirnaty, guidelines mRNA COVID vaccine, mandatory vaccination during pregnancy

Abstract

The objective of this note is to analyse the safety assessment of Comirnaty vaccination of pregnant women in the manufacturer’s risk management plan (RMP) and in the European Medicines Agency (EMA) fact sheet, and to measure the impact on the recommendations that led to the mandatory vaccination of pregnant women caregivers and health-related professionals in France.

The evaluation of this safety was carried out in two phases. In the first phase, which ran from late 2020 to early 2022, the safety profile of the vaccine was not known in pregnant women. In the second phase, which ran from early 2022, the RMP and the EMA report data that were considered reassuring for short-term safety, but were limited. Long-term safety remains still unknown. The RMP is cautious and suggests that intentional injection of pregnant women will remain limited.

The detailed analysis of risk management by the manufacturer, the EMA and the French authorities reveals, to varying degrees, a lack of rigor. The EMA has disregarded certain elements of prudence maintained by the manufacturer, while the manufacturer has allowed the only real clinical trial that might determine any benefit-risk balance to lapse. What is more the only study was restricted to the third trimester of pregnancy. The French authorities recommended mandatory injection of pregnant women caregivers and health-related professionals at a time when the manufacturer and the EMA could provide no guarantees.

Author Biography

  • Jérôme Sainton, Independent Medical Doctor and bioethicist

    Engineer, General practitioner, Bioethicist, Cabinet médical « Le Ruisseau », Reims 51100, France

References

Bardosh, K., Krug, A., Jamrozik, E., Lemmens, T., Keshavjee, S., Prasad, V., Makary, M. A., Baral, S., & Høeg, T. B. (2022). COVID-19 vaccine boosters for young adults: A risk benefit assessment and ethical analysis of mandate policies at universities. Journal of Medical Ethics. https://doi.org/10.1136/jme-2022-108449

Brock, A. R., & Thornley, S. (2021). Spontaneous Abortions and Policies on COVID-19 mRNA Vaccine Use During Pregnancy. Science, Public Health Policy, and the Law, 4, 130–143. https://cf5e727d-d02d-4d71-89ff-9fe2d3ad957f.filesusr.com/ugd/adf864_2bd97450072f4364a65e5cf1d7384dd4.pdf

Chiu, S.-N., Chen, Y.-S., Hsu, C.-C., Hua, Y.-C., Tseng, W.-C., Lu, C.-W., Lin, M.-T., Chen, C.-A., Wu, M.-H., Chen, Y.-T., Chien, T.-C. H., Tseng, C.-L., & Wang, J.-K. (2023). Changes of ECG parameters after BNT162b2 vaccine in the senior high school students. European Journal of Pediatrics, 1–8. https://doi.org/10.1007/s00431-022-04786-0

COSV. (2021a). Avis du 6 avril 2021: Élargissement des priorités d’accès à la vaccination anti-COVID-19. https://www.mesvaccins.net/textes/avis_du_cosv_6_avril_2021pdf.pdf

COSV. (2021b). Avis du 21 juillet 2021: Concernant la vaccination des femmes enceintes au cours du 1er trimestre. https://www.mesvaccins.net/textes/20210721_cosv_vaccination_femmes_enceintes.pdf

Cunningham, A. S. (2021). Why don’t COVID-19 vaccine trials report statistics for the first 14 days? https://www.bmj.com/content/372/bmj.n728/rr-0

Doshi, P. (2020, November 26). Pfizer and Moderna’s “95% effective” vaccines—Let’s be cautious and first see the full data. The BMJ. https://blogs.bmj.com/bmj/2020/11/26/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data/

Doshi, P. (2021a, January 4). Pfizer and Moderna’s “95% effective” vaccines—We need more details and the raw data. The BMJ. https://blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/

Doshi, P. (2021b, February 5). Clarification: Pfizer and Moderna’s “95% effective” vaccines—we need more details and the raw data. The BMJ. https://blogs.bmj.com/bmj/2021/02/05/clarification-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/

EMA. (n.d.). Comirnaty. European Medicines Agency. Retrieved January 20, 2023, from https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty

EMA. (2020, December 24). Comirnaty | European Medicines Agency. https://web.archive.org/web/20201224012625/https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty

EMA. (2021a). Assessment report: Comirnaty (EMA/707383/2020). European Medicines Agency. https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf

EMA. (2021b, November 27). Comirnaty | European Medicines Agency. https://web.archive.org/web/20211127003600/https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty

EMA. (2022a, January 18). COVID-19: Latest safety data provide reassurance about use of mRNA vaccines during pregnancy [Text]. European Medicines Agency. https://www.ema.europa.eu/en/news/covid-19-latest-safety-data-provide-reassurance-about-use-mrna-vaccines-during-pregnancy

EMA. (2022b, March 4). Comirnaty | European Medicines Agency. https://web.archive.org/web/20220304093350/https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty

EMA. (2022c, September 2). Comirnaty | European Medicines Agency. https://web.archive.org/web/20220902182626/https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty

EMA. (2022d, September 20). Comirnaty | European Medicines Agency. https://web.archive.org/web/20220920090940/https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty

Fraiman, J., Erviti, J., Jones, M., Greenland, S., Whelan, P., Kaplan, R. M., & Doshi, P. (2022). Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine, 40(40), 5798–5805. https://doi.org/10.1016/j.vaccine.2022.08.036

Garner, J. (2022). Health versus Disorder, Disease, and Death: Unvaccinated Persons Are Incommensurably Healthier than Vaccinated. International Journal of Vaccine Theory, Practice, and Research, 2(2), 670–686. https://doi.org/10.56098/ijvtpr.v2i2.40

Gat, I., Kedem, A., Dviri, M., Umanski, A., Levi, M., Hourvitz, A., & Baum, M. (2022). COVID-19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors. Andrology, n/a(n/a). https://doi.org/10.1111/andr.13209

HAS. (2021a). Stratégie de vaccination contre le SARS-CoV-2—Actualisation des facteurs de risque de formes graves de la COVID-19 et des recommandations sur la stratégie de priorisation des populations à vacciner. https://www.has-sante.fr/jcms/p_3240117/fr

HAS. (2021b). Avis n° 2021.0047/AC/SEESP du 8 juillet 2021 du collège de la Haute Autorité de santé relatif à l’adaptation de la stratégie vaccinale devant l’émergence de variants du SARS-CoV-2. https://www.has-sante.fr/jcms/p_3277121/fr

HAS. (2021c). Avis n° 2021.0052/AC/SEESP du 15 juillet 2021 du collège de la Haute Autorité de santé relatif au projet de loi relatif à l’adaptation de nos outils de gestion de la crise sanitaire. https://has-sante.fr/jcms/p_3278245/fr

HAS. (2022). Avis n°2022.0044/AC/SESPEV du 21 juillet 2022 du collège de la Haute Autorité de santé relatif à l’obligation de vaccination contre la COVID-19 des professionnels des secteurs sanitaire et médico-social. https://has-sante.fr/jcms/p_3356224/fr

Kachikis, A., Englund, J. A., Singleton, M., Covelli, I., Drake, A. L., & Eckert, L. O. (2021). Short-term Reactions Among Pregnant and Lactating Individuals in the First Wave of the COVID-19 Vaccine Rollout. JAMA Network Open, 4(8), e2121310. https://doi.org/10.1001/jamanetworkopen.2021.21310

Kharbanda, E. O., Haapala, J., DeSilva, M., Vazquez-Benitez, G., Vesco, K. K., Naleway, A. L., & Lipkind, H. S. (2021). Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy. JAMA, 326(16), 1629–1631. https://doi.org/10.1001/jama.2021.15494

Laganà, A. S., Veronesi, G., Ghezzi, F., Ferrario, M. M., Cromi, A., Bizzarri, M., Garzon, S., & Cosentino, M. (2022). Evaluation of menstrual irregularities after COVID-19 vaccination: Results of the MECOVAC survey. Open Medicine, 17(1), 475–484. https://doi.org/10.1515/med-2022-0452

Lipkind, H. S. (2022). Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth—Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021. MMWR. Morbidity and Mortality Weekly Report, 71. https://doi.org/10.15585/mmwr.mm7101e1

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., Brown, K., Cameron, C., Stockton, D., McMenamin, J., & Ramsay, M. (2021). Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. The BMJ, 373, n1088. https://doi.org/10.1136/bmj.n1088

Male, V. (2021). Are COVID-19 vaccines safe in pregnancy? Nature Reviews Immunology, 21(4), Article 4. https://www.nature.com/articles/s41577-021-00525-y

Mansanguan, S., Charunwatthana, P., Piyaphanee, W., Dechkhajorn, W., Poolcharoen, A., & Mansanguan, C. (2022). Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents. Tropical Medicine and Infectious Disease, 7(8), Article 8. https://doi.org/10.3390/tropicalmed708019

Moustsen-Helms, I. R., Emborg, H.-D., Nielsen, J., Nielsen, K. F., Krause, T. G., Mølbak, K., Møller, K. L., Berthelsen, A.-S. N., & Valentiner-Branth, P. (2021). Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA COVID-19 Vaccine in long-term care facility residents and healthcare workers – a Danish cohort study. https://doi.org/10.1101/2021.03.08.21252200

Nance, K. D., & Meier, J. L. (2021). Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Central Science, 7(5), 748–756. https://doi.org/10.1021/acscentsci.1c00197

Neil, M., Fenton, N., Smalley, J., Craig, C., Guetzkow, J., McLachlan, S., Engler, J., Russell, D., & Rose, J. (2022). Official mortality data for England suggest systematic miscategorisation of vaccine status and uncertain effectiveness of COVID-19 vaccination. https://doi.org/10.13140/RG.2.2.28055.09124

NEMJ ed. (2021). Correction: Preliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons. New England Journal of Medicine, 385(16), 1536–1536. https://doi.org/10.1056/NEJMx210016

Onakpoya, I. J. (2018). Rare adverse events in clinical trials: Understanding the rule of three. BMJ Evidence-Based Medicine, 23(1), 6–6. https://doi.org/10.1136/ebmed-2017-110885

Pfizer. (n.d.). Comirnaty (COVID-19 mRNA vaccine)—Risk Management Plan. Retrieved January 21, 2023, from https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf

Pfizer. (2020). Comirnaty (COVID-19 mRNA vaccine)—Risk Management Plan—Version number: 1.0. https://web.archive.org/web/20210203153702/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf

Pfizer. (2021a). Comirnaty (COVID-19 mRNA vaccine)—Risk Management Plan—Version number: 1.1. https://web.archive.org/web/20210505230527/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf

Pfizer. (2021b). Comirnaty (COVID-19 mRNA vaccine)—Risk Management Plan—Version number: 2.0. https://web.archive.org/web/20210602082901/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf

Pfizer. (2021c). Comirnaty (COVID-19 mRNA vaccine)—Risk Management Plan—Version number: 2.3. https://web.archive.org/web/20211114215356/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf

Pfizer. (2021d). Comirnaty (COVID-19 mRNA vaccine)—Risk Management Plan—Version number: 4.0. https://web.archive.org/web/20211218222945/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf

Pfizer. (2022a). Comirnaty (COVID-19 mRNA vaccine)—Risk Management Plan—Version number: 5.0. https://web.archive.org/web/20220415130551/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf

Pfizer. (2022b). Comirnaty (COVID-19 mRNA vaccine)—Risk Management Plan—Version number: 7.1. https://web.archive.org/web/20220930091217/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf

Pfizer. (2022c). Comirnaty (COVID-19 mRNA vaccine)—Risk Management Plan—Version number: 9.0. https://web.archive.org/web/20221124135059/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf

Public Health Ontario. (2021). Confirmed Cases of COVID-19 Following Vaccination in Ontario: December 14, 2020 to October 31, 2021. http://web.archive.org/web/20211122182311/https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-epi-confirmed-cases-post-vaccination.pdf

Rasmussen, S. A., & Jamieson, D. J. (2021). Pregnancy, Postpartum Care, and COVID-19 Vaccination in 2021. JAMA, 325(11), 1099–1100. https://doi.org/10.1001/jama.2021.1683

Romero, E., Fry, S., & Hooker, B. (2023). Safety of mRNA injectables administered during the first twenty-four months of the international COVID-19 injection program. International Journal of Vaccine Theory, Practice, and Research, 3(1), 891–910. https://doi.org/10.56098/ijvtpr.v3i1.70

Segalla, G. (2023). Chemical-physical criticality and toxicological potential of lipid nanomaterials contained in a COVID-19 mRNA vaccine. International Journal of Vaccine Theory, Practice, and Research, 3(1), 787–817. https://doi.org/10.56098/ijvtpr.v3i1.68

Seneff, S., & Nigh, G. (2021). Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19. International Journal of Vaccine Theory, Practice, and Research, 2(1), 38–79. https://doi.org/10.56098/ijvtpr.v2i1.23

Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., Marquez, P. L., Olson, C. K., Liu, R., Chang, K. T., Ellington, S. R., Burkel, V. K., Smoots, A. N., Green, C. J., Licata, C., Zhang, B. C., Alimchandani, M., Mba-Jonas, A., Martin, S. W., … Meaney-Delman, D. M. (2021a). Preliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons (original publication). https://web.archive.org/web/20210904040636/https://www.nejm.org/doi/pdf/10.1056/NEJMoa2104983?articleTools=true

Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., Marquez, P. L., Olson, C. K., Liu, R., Chang, K. T., Ellington, S. R., Burkel, V. K., Smoots, A. N., Green, C. J., Licata, C., Zhang, B. C., Alimchandani, M., Mba-Jonas, A., Martin, S. W., … Meaney-Delman, D. M. (2021b). Preliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons. New England Journal of Medicine, 384(24), 2273–2282. https://doi.org/10.1056/NEJMoa2104983

Stock, S. J., Carruthers, J., Calvert, C., Denny, C., Donaghy, J., Goulding, A., Hopcroft, L. E. M., Hopkins, L., McLaughlin, T., Pan, J., Shi, T., Taylor, B., Agrawal, U., Auyeung, B., Katikireddi, S. V., McCowan, C., Murray, J., Simpson, C. R., Robertson, C., … Wood, R. (2022). SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. Nature Medicine, 28(3), Article 3. https://doi.org/10.1038/s41591-021-01666-2

Sun, C. L. F., Jaffe, E., & Levi, R. (2022). Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave. Scientific Reports, 12(1), 6978. https://doi.org/10.1038/s41598-022-10928-z

Totura, A. L., & Bavari, S. (2019). Broad-spectrum coronavirus antiviral drug discovery. Expert Opinion on Drug Discovery, 14(4), 397–412. https://doi.org/10.1080/17460441.2019.1581171

Tripepi, G., Jager, K. J., Dekker, F. W., & Zoccali, C. (2010). Selection Bias and Information Bias in Clinical Research. Nephron Clinical Practice, 115(2), c94–c99. https://doi.org/10.1159/000312871

UK Health Security Agency. (2021). COVID-19 vaccine surveillance report—Week 47. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036047/Vaccine_surveillance_report_-_week_47.pdf

Downloads

Published

2023-04-12

How to Cite

Assessment of Comirnaty Injections of Pregnant Women in the Manufacturer’s Risk Management Plan and by the European Medicines Agency: Mandatory Injections for Caregivers in France. (2023). International Journal of Vaccine Theory, Practice, and Research , 3(1), 911-928. https://doi.org/10.56098/ijvtpr.v3i1.72

Similar Articles

1-10 of 46

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>